Lv51
893 积分 2021-08-19 加入
Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
2小时前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
2小时前
已完结
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
2小时前
已完结
Management of Thyroid Disorders in Pregnancy
4个月前
已完结
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
5个月前
已完结
Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-difference trial
5个月前
已完结
Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients without ASCVD: The VICTORION-Mono Randomized Clinical Trial
5个月前
已完结
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
5个月前
已完结
Safety and efficacy of inclisiran in treating hypercholesterolemia: A systemic review and meta-analysis
5个月前
已完结
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
5个月前
已完结
皖公网安备34019202002308
